tachypnea

[키워드] 1:1 48 hours Adverse reaction Adverse reactions age approved Arm Bandar Abbas Blinding block randomization blood pressure Care checked chronic lung disease clinical clinical symptom clinical trial clinical trials Committee company comparator Patients composite endpoint control group Controlled clinical trial controls Coronary heart disease COVID-19 COVID-19 patient COVID-19 patients CRP Deep vein Deep vein thrombosis diabetes Diabetes Mellitus Diastolic blood pressure dissemination distilled water Efficacy and safety element End-stage renal disease endogenous enoxaparin erythropoietin ethics committee evaluate evaluate the effect excluded exclusion criteria expected Haemoglobin Health Health care heart disease hospitalised hospitalised COVID-19 patients Hypoxemia immune system infiltration injection intervals Intervention intervention group investigator Iran Laboratory test Laboratory tests LDH Liver disease Local Lung disease lung field lung infiltration lymphocyte Lymphocyte count lymphopenia Medical Science Medical Sciences medication minute number objective oral contraceptive outcome oxygen oxygen partial pressure oxygen saturation parallel-group partial pressure participant Patient PCR performed pharmaceutical Pharmaceutical Company Phase 2 Placebo positive Prevent principal investigator protocol randomised randomised controlled trial Randomized Randomly receive recombinant erythropoietin recruitment Registered registry renal disease reported respiratory respiratory rate Sample size saturation severe COVID-19 symptom severe COVID-19 symptoms Side effect Side effects Standard Standard of care status sterile water Study protocol subcutaneous injection subject supplementary material Systolic blood pressure tachypnea technology the ethics committee thrombosis title Treatment protocol treatment protocols Trial registration university vital signs water water for injection weakened immune system website
[DOI] 10.1186/s13063-021-05363-w PMC 바로가기 [Article Type] Letter